Early treatment is critical to protecting your sight if you have glaucoma, however traditional surgery and medication are not always ideal. If you are planning to undergo cataract surgery for concomitant cataract and glaucoma, the Alcon CyPass® Micro-Stent provides a minimally invasive option. Our team of doctors at Southwest Eye Care and Laser can perform this state-of-the-art glaucoma treatment at our Bakersfield, CA, office. This procedure can safely reduce the pressure inside of your eye, so you achieve long-term control over your glaucoma without medication.
The CyPass Micro-Stent can reduce intraocular pressure when placed during cataract surgery.
The CyPass Micro-Stent is a device approved by the Food and Drug Administration (FDA) for the treatment of mild to moderate glaucoma. The device is implanted during cataract surgery and is a less invasive alternative to traditional surgery. The small, cylindrical implant is surgically placed in the space between the sclera (the white outer layer of the eye) and ciliary body (the circular structure behind the iris) during cataract surgery.
A clinical study released by the FDA showed that 72.5 percent of patients treated with the CyPass Micro-Stent achieved a significantly lower intraocular pressure.
Designed to promote the flow of excess fluid from the eye, the cylinder has an entry port at one end and microscopic holes throughout the stem to diffuse liquid as it passes through. The micro-stent is biocompatible and made using polyamide, which promotes drainage through the device to help decrease intraocular pressure, or IOP.
One of our doctors can help you determine if you are a good candidate for minimally invasive glaucoma surgery (MIGS) based on the extent of your condition and whether or not you have undergone previous treatments. Generally, the CyPass Micro-Stent is an appropriate option for:
The Micro-Stent is currently not considered an appropriate treatment option for:
Prior to recommending treatment, our doctors can review each of your options and take the time to answer any questions as well as address concerns.
According to the National Center for Biotechnology Information, this minimally invasive approach to glaucoma treatment can allow the eye to drain while preserving healthy surrounding tissue, reducing your surgery time, and expediting the length of your recovery.
A clinical study released by the FDA showed that 72.5 percent of patients treated with the CyPass Micro-Stent achieved a significantly lower intraocular pressure, while only 58 percent of patients who had traditional cataract surgery were able to achieve lower eye pressure. Another study released by the American Academy of Ophthalmology also found that a majority of patients who underwent MIGS surgery achieved a stable IOP and had reduced medication use by 75 percent one year after the procedure. The study also cited the CyPass Micro-Stent as demonstrating a high safety profile.
Glaucoma medication and eye drops can be difficult for patients to administer at home and can be ineffective for the long-term control of intraocular pressure. CyPass is designed to reduce the dependency on medication.
Traditional glaucoma surgery also has an increased risk of complications including hypotony, hyphema, and bleb damage. The MicroStent placement is less invasive and minimizes the risk of complications. It is equally effective at reducing pressure and dependency on glaucoma medication.
Early glaucoma diagnosis is the key to ensuring safe, effective treatment, and the CyPass Micro-Stent provides a minimally invasive treatment option. To schedule an eye exam or discuss glaucoma treatment options with one of our doctors, call Southwest Eye Care and Laser at (661) 393-2331 or contact our team online.